Aileen David-Wang
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Asthma and respiratory diseases 6
- Clinical Laboratory Practices and Quality Control 1
-
- COVID-19 Clinical Research Studies 3
- Co-authors
- Kenneth R. Chapman (2 shared papers)Steven Kesten (1 shared paper)Nicola Alexander Hanania (1 shared paper)Sang‐Heon Cho (4 shared papers)David Price (4 shared papers)Nicholas A. Kartsonis (1 shared paper)Richard G. Wunderink (1 shared paper)Helen W. Boucher (1 shared paper)
- Journals
- The Lancet (1 paper)Clinical Infectious Diseases (1 paper)Allergy Asthma and Immunology Research (1 paper)Value in Health Regional Issues (1 paper)Therapeutic Drug Monitoring (1 paper)
- Partner nations
- PhilippinesSouth KoreaHong Kong
In The Last Decade
Aileen David-Wang
13 papers receiving 648 citations
Aileen David-Wang's Hit Papers
Peers
Comparison fields: 5 of 59
- Molecular Medicine 132
- Infectious Diseases 231
- Applied Microbiology and Biotechnology 17
- Critical Care and Intensive Care Medicine 28
- Physiology 147
Countries citing papers authored by Aileen David-Wang
This map shows the geographic impact of Aileen David-Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aileen David-Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aileen David-Wang more than expected).
Fields of papers citing papers by Aileen David-Wang
This network shows the impact of papers produced by Aileen David-Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aileen David-Wang. The network helps show where Aileen David-Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Aileen David-Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses Hit paper breakdown → | 2022 | 290 |
| 2 | 2020 | 173 | |
| 3 | 2015 | 83 | |
| 4 | 1997 | 69 | |
| 5 | 2016 | 21 | |
| 6 | 2016 | 10 | |
| 7 | 2017 | 8 | |
| 8 | 2018 | 5 | |
| 9 | 2023 | 3 | |
| 10 | 2014 | 2 | |
| 11 | 2021 | 2 | |
| 12 | 1994 | 1 | |
| 13 | 2019 | 1 | |
| 14 | 2023 | 1 | |
| 15 | 2025 | 0 |
About Aileen David-Wang
Aileen David-Wang is a scholar working on Physiology, Infectious Diseases, Oncology, Critical Care and Intensive Care Medicine and Toxicology, having authored 15 papers that have together received 669 indexed citations. Recurring topics across this work include Asthma and respiratory diseases (6 papers), COVID-19 Clinical Research Studies (3 papers), Nosocomial Infections in ICU (1 paper), Clinical Laboratory Practices and Quality Control (1 paper), COVID-19 and healthcare impacts (1 paper), Pneumonia and Respiratory Infections (1 paper), Biosimilars and Bioanalytical Methods (1 paper) and Cancer Diagnosis and Treatment (1 paper). The work is most often cited by research in Molecular Medicine (132 citations), Infectious Diseases (231 citations), Applied Microbiology and Biotechnology (17 citations), Critical Care and Intensive Care Medicine (28 citations) and Physiology (147 citations). Aileen David-Wang has collaborated with scholars based in Philippines, South Korea and Hong Kong. Frequent co-authors include Kenneth R. Chapman, Steven Kesten, Nicola Alexander Hanania, Sang‐Heon Cho, David Price, Nicholas A. Kartsonis, Richard G. Wunderink, Helen W. Boucher, Antoine Roquilly and Ivan Titov. Their work appears in journals such as The Lancet, Clinical Infectious Diseases, Allergy Asthma and Immunology Research, Value in Health Regional Issues and Therapeutic Drug Monitoring.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.